Comparison of Empagliflozin with other SGLT-2i and the Pharmacological Effects of Empagliflozin

Diabetes mellitus is a pathological illness that is distinguished by compromised metabolic function due to defects in the synthesis and response of insulin, leading to substantial health complications. T2D is now recognized as a pressing global health concern, affecting a large population worldwide. Several studies have demonstrated that Empagliflozin can be categorized as a member of the drug class known as SGLT-2 inhibitors (SGLT-2i). This particular medication has been found to be effective in the treatment of T2D. This article elucidates the pharmacological effects of the substance in question, namely its capacity to reduce blood glucose levels, provide cardioprotection (mitigation of oxidative stress in the myocardium, mitigation of cardiac inflammation, decrease cell death in the cardiac tissue, betterment of Disrupted Electrolyte Homeostasis), influence cardiovascular outcomes, address obesity, impact renal function, and perhaps exhibit anticancer properties. The present study also aims to examine the comparative effects of empagliflozin in relation to other inhibitors across various domains, including cardiovascular events, worsening renal function, metabolic outcomes, and all-cause mortality.